Selective Tyk2 Inhibitor Articles & Analysis: Older
1 news found
Immunology We have built up over 20 years of expertise in immunology, resulting in a deep and growing pipeline with multiple modes-of-action candidate medicines across all phases of development, from preclinical to Phase 4. We are excited about our selective TYK2 inhibitor, ‘3667, for which we presented new data elucidating its ...